The U.S. Treasury Department is closing in on American investments in China's life sciences industry as it issued draft rules ...

As a snarl of pharma-focused lawsuits from Texas Attorney General Ken Paxton play out, Gilead Sciences has worked out a deal ...

Yesterday, argenx's stock slipped by more than 2%—with its shares still down slightly as of Friday morning—after the Dutch ...

In this week's episode of "The Top Line," we're covering a pair of FDA approvals for GSK, an antibody-drug conjugate pact ...

Pfizer’s newest round of workforce cuts may be getting an early start.  | Local news reported Pfizer layoffs in Michigan and ...

After disappointing Wall Street for most of 2026, Roche’s eye disease drug Vabysmo met analysts’ expectations for the first ...

The FDA rebuked Baxter in a lengthy warning letter that outlined a series of production violations that led to a trio of ...

In its own approval announcement on Oct. 20, the FDA hailed Hibsago as a “first-of-its-kind” treatment in chronic hepatitis B ...

This week, the companies announced wins across their late-stage Clarity-1 and Clarity-2 studies of once-daily brepocitinib in ...

With a late Thursday nod from the FDA to reduce protein levels in the urine of patients with primary immunoglobulin A ...

Alcon—the eye-focused pharma spun out of Novartis—is handing over $550 million to buy out Neurotech Pharmaceuticals, its ...

Esteve CDMO, the contract development and manufacturing organization within Spanish specialty pharma Esteve, is overhauling ...